Applied Molecular Transport to Report Top-line Phase 2 Results from MARKET Combination Trial of Oral AMT-101 in Patients with Moderate-to-Severe Ulcerative Colitis
06 July 2022 - 6:01AM
Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT) today
announced that the company plans to report top-line data results
from its Phase 2 MARKET combination trial of AMT-101 (GI-
selective, oral fusion of IL-10) with anti-TNFα in biologic-naïve
patients with moderate-to-severe ulcerative colitis. The company
will issue a premarket press release and host a live webcasted
conference call on Wednesday, July 6, 2022, at 8:30 a.m. ET (5:30
a.m. PT).
Conference Call & Webcast
InformationTo join the conference call via phone and
participate in the live Q&A session, please pre-register online
here to receive a telephone number and unique passcode required to
enter the call. A live webcast will be available on the Events page
of the Applied Molecular Transport website at
https://ir.appliedmt.com/news-events/events. An archived replay
will be available for 30 days following the event.
About Applied Molecular Transport
Inc.AMT is a clinical-stage biopharmaceutical company
developing novel oral biologic product candidates, by leveraging
its technology platform to design biologic product candidates in
patient friendly oral dosage forms. AMT’s product candidates are
designed to precisely target the relevant pathophysiology of
disease. AMT’s proprietary technology platform is incorporated in
its product candidates, exploiting existing natural cellular
trafficking pathways to drive the active transport of diverse
therapeutic modalities across the IE barrier. Active transport is
an efficient mechanism that utilizes the cell’s own machinery to
transport materials across the IE barrier.
AMT’s headquarters, internal GMP manufacturing
and lab facilities are located in South San Francisco, CA. For
additional information on AMT, please visit www.appliedmt.com.
Investor Relations
Contact:Andrew ChangHead, Investor Relations &
Corporate Communicationsachang@appliedmt.com
Media Contacts:Alexandra
SantosWheelhouse Life Science Advisorsasantos@wheelhouselsa.com
Aljanae ReynoldsWheelhouse Life Science
Advisorsareynolds@wheelhouselsa.com
Applied Molecular Transp... (NASDAQ:AMTI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Applied Molecular Transp... (NASDAQ:AMTI)
Historical Stock Chart
From Apr 2023 to Apr 2024